A Randomised Trial of Two Radiotherapy Schedules in the Adjuvant Treatment of Stage I Seminoma (MRC TE18) — Preliminary Report

  • W. G. Jones
  • S. D. Fossa
  • G. M. Mead
  • J. T. Roberts
  • M. Sokal
  • S. Naylor
  • S. P. Stenning
  • MRC Testicular Tumour Working Party

Abstract

Adjuvant post-orchidectomy radiotherapy cures the majority of patients with stage I seminoma, but as approximately 80 per cent would remain relapse-free on surveillance alone, minimising radiotherapy — and hence morbidity and second cancer risk — is a worthwhile aim. An earlier MRC trial (TE10) assessed the impact of reducing radiotherapy field size from the dog-leg field to the para-aortic strip only. This follow-on trial assessed the impact of reducing radiotherapy dose on relapse rates, acute morbidity and quality of life.

Keywords

Seminoma 

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • W. G. Jones
    • 1
  • S. D. Fossa
    • 1
  • G. M. Mead
    • 1
  • J. T. Roberts
    • 1
  • M. Sokal
    • 1
  • S. Naylor
    • 1
  • S. P. Stenning
    • 1
  • MRC Testicular Tumour Working Party
    • 1
  1. 1.MRC Clinical Trials UnitLondonUK

Personalised recommendations